NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1035 coverProtective Strategies for Neurodegenerative Diseases Volume 1035 published December 2004
Ann. N.Y. Acad. Sci. 1035: 231–249 (2004). doi: 10.1196/annals.1332.015
Copyright © 2004 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by VERNIER, P.
Articles by SIDHU, A.
Search for Related Content
PubMed
PubMed Citation
Articles by VERNIER, P.
Articles by SIDHU, A.
The Degeneration of Dopamine Neurons in Parkinson's Disease: Insights from Embryology and Evolution of the Mesostriatocortical System

PHILIPPE VERNIERa, FREDERIC MORETa, SOPHIE CALLIERa, MARINA SNAPYANa, CHRISTOPHE WERSINGERb AND ANITA SIDHUb

aDevelopment, Evolution, Plasticity of the Nervous System, Institute of Neurobiology A. Fessard, CNRS, 91198 Gif-sur-Yvette, France
bDepartment of Pediatrics, Georgetown University, Washington, District of Columbia 20007, USA

Address for correspondence: Dr. Philippe Vernier, Development, Evolution, Plasticity of the Nervous System, UPR2197, Institute of Neurobiology A. Fessard, CNRS, 91198 Gif-sur-Yvette, France. Voice: +33-169-823-430; fax: +33-169-823-447. vernier{at}iaf.cnrs-gif.fr

Parkinson's disease (PD) is, to a large extent, specific to the human species. Most symptoms are the consequence of the preferential degeneration of the dopamine-synthesizing cells of the mesostriatal-mesocortical neuronal pathway. Reasons for that can be traced back to the evolutionary mechanisms that shaped the dopamine neurons in humans. In vertebrates, dopamine-containing neurons and nuclei do not exhibit homogenous phenotypes. In this respect, mesencephalic dopamine neurons of the substantia nigra and ventral tegmental area are characterized by a molecular combination (tyrosine hydroxylase, aromatic amino acid decarboxylase, monoamine oxidase, vesicular monoamine transporter, dopamine transporter—to name a few), which is not found in other dopamine-containing neurons of the vertebrate brain. In addition, the size of these mesencephalic DA nuclei is tremendously expanded in humans as compared to other vertebrates. Differentiation of the mesencephalic neurons during development depends on genetic mechanisms, which also differ from those of other dopamine nuclei. In contrast, pathophysiological approaches to PD have highlighted the role of ubiquitously expressed molecules such as a-synuclein, parkin, and microtubule-associated proteins. We propose that the peculiar phenotype of the dopamine mesencephalic neurons, which has been selected during vertebrate evolution and reshaped in the human lineage, has also rendered these neurons particularly prone to oxidative stress, and thus, to the fairly specific neurodegeneration of PD. Numerous evidence has been accumulated to demonstrate that perturbed regulation of DAT-dependent dopamine uptake, DAT-dependent accumulation of toxins, dysregulation of TH activity as well as high sensitivity of DA mesencephalic neurons to oxidants are key components of the neurodegeneration process of PD. This view points to the contribution of nonspecific mechanisms ({alpha}-synuclein aggregation) in a highly specific cellular environment (the dopamine mesencephalic neurons) and provides a robust framework to develop novel and rational therapeutic schemes in PD.

Key Words: Parkinson's disease (PD) • development • dopamine transporter • dopamine receptors • {alpha}-synuclein • neuroprotection




This article has been cited by other articles:


Home page
Genome Res.Home page
D. B. McClatchy, L. Liao, S. K. Park, J. D. Venable, and J. R. Yates
Quantification of the synaptosomal proteome of the rat cerebellum during post-natal development
Genome Res., September 1, 2007; 17(9): 1378 - 1388.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
B. L. Schneider, C. R. Seehus, E. E. Capowski, P. Aebischer, S.-C. Zhang, and C. N. Svendsen
Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation
Hum. Mol. Genet., March 15, 2007; 16(6): 651 - 666.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
T.-K. Sang, H.-Y. Chang, G. M. Lawless, A. Ratnaparkhi, L. Mee, L. C. Ackerson, N. T. Maidment, D. E. Krantz, and G. R. Jackson
A Drosophila Model of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine
J. Neurosci., January 31, 2007; 27(5): 981 - 992.
[Abstract] [Full Text] [PDF]



footerLeft footerRight